Teladoc Health
TDOC
5.56
-0.21
-3.64%
Teladoc Health
US · TDOC
#3241 by market cap
Listed 2015
5.56
-0.21
-3.64%
Live - 5344 symbols - heartbeat 276s ago
· 2026-10-08 09:19
Pre-market
5.55
-0.18%
After-hours
5.56
0.00%
- Market cap
- 1.01B
- P/E (TTM)i
- -5.62
- P/Bi
- 0.77
- EPSi
- -1.14
- Div yieldi
- 0.00%
- 52W posi
- 21%
Reader sentiment
Are you bullish or bearish on TDOC?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -6.64, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -1.54% YoY
Margins
- Gross margin
- 69.50%
- Operating margin
- -6.46%
- Net margin
- -7.92%
Key ratios & quality
- Enterprise valuei
- 1.24B
- Altman Z-Scorei
- -6.64
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 417.91M | 553.31M | 1.09B | 2.03B | 2.41B | 2.60B | 2.57B | 2.53B |
| Gross profit | 289.17M | 368.84M | 703.13M | 1.38B | 1.66B | 1.84B | 1.82B | 1.76B |
| Selling & admin expenses | 265.16M | 339.07M | 886.88M | 1.11B | 1.30B | 1.37B | 1.35B | 1.28B |
| Research & development | 54.37M | 64.64M | 164.94M | 311.88M | 333.63M | 348.52M | 307.27M | 277.92M |
| Operating profit | -65.96M | -73.82M | -418.19M | -238.99M | -227.37M | -210.50M | -208.79M | -163.40M |
| Pretax profit | -96.97M | -109.46M | -575.99M | -384.66M | -13.66B | -219.61M | -993.65M | -235.53M |
| Tax | 118.00K | -10.59M | -90.86M | 44.14M | -3.81M | 760.00K | 7.59M | -35.21M |
| Net profit | -97.08M | -98.86M | -485.14M | -428.79M | -13.66B | -220.37M | -1.00B | -200.32M |
| Basic EPS | -1 | -1 | -5 | -3 | -85 | -1 | -6 | -1 |
| Diluted EPS | -1.47 | -1.38 | -5.36 | -2.73 | -84.60 | -1.34 | -5.87 | -1.14 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 629.37M | 631.90M | 626.44M | 642.27M | 613.85M | 606.93M |
| Gross profit | 432.54M | 441.36M | 439.26M | 445.22M | 416.32M | 416.09M |
| Selling & admin expenses | 329.65M | 325.61M | 318.78M | 305.74M | 304.90M | 296.82M |
| Research & development | 69.96M | 68.78M | 67.57M | 71.61M | 67.87M | 62.86M |
| Operating profit | -54.94M | -46.04M | -35.46M | -26.97M | -48.73M | -34.50M |
| Pretax profit | -111.27M | -40.42M | -50.22M | -33.62M | -60.84M | -37.91M |
| Tax | -18.26M | -7.76M | -715.00K | -8.48M | 3.00M | 997.00K |
| Net profit | -93.01M | -32.66M | -49.51M | -25.14M | -63.84M | -38.91M |
| Basic EPS | -1 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.53 | -0.19 | -0.28 | -0.14 | -0.36 | -0.21 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 532.74M | 588.00M | 1.06B | 1.23B | 1.32B | 1.49B | 1.66B | 1.12B |
| Cash & ST investments | 478.53M | 517.06M | 786.57M | 896.02M | 918.18M | 1.12B | 1.30B | 781.08M |
| Inventory | -- | 0 | 56.50M | 73.08M | 56.34M | 29.51M | 38.14M | 38.20M |
| Total assets | 1.53B | 1.60B | 17.76B | 17.73B | 4.35B | 4.39B | 3.52B | 2.86B |
| Total current liabilities | 62.44M | 90.18M | 332.65M | 331.01M | 399.77M | 420.62M | 941.54M | 404.74M |
| Short-term debt | -- | 5.09M | 54.00M | 12.69M | 13.59M | 10.75M | 561.06M | 11.04M |
| Long-term debt | 414.68M | 440.41M | 1.38B | 1.23B | 1.54B | 1.54B | 991.42M | 994.93M |
| Total liabilities | 515,757,000.00 | 588,802,000.00 | 1,871,477,000.00 | 1,688,851,000.00 | 2,037,610,000.00 | 2,066,296,000.00 | 2,025,445,000.00 | 1,472,594,000.00 |
| Total equity | 1.01B | 1.01B | 15.88B | 16.05B | 2.31B | 2.33B | 1.49B | 1.39B |
| Retained earnings | -408.66M | -507.53M | -992.66M | -1.42B | -15.01B | -15.23B | -16.23B | -16.43B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.60B | 1.07B | 1.09B | 1.12B | 1.13B | 1.15B |
| Cash & ST investments | 1.19B | 679.62M | 726.25M | 781.08M | 750.74M | 774.35M |
| Inventory | 38.01M | 38.16M | 39.90M | 38.20M | 31.56M | 28.82M |
| Total assets | 3.44B | 2.89B | 2.88B | 2.86B | 2.81B | 2.76B |
| Total current liabilities | 952.42M | 401.77M | 405.09M | 404.74M | 404.87M | 1.38B |
| Short-term debt | 560.69M | 9.88M | 10.23M | 11.04M | 10.50M | 1.01B |
| Long-term debt | 992.29M | 993.17M | 994.04M | 994.93M | 995.81M | -- |
| Total liabilities | 2,017,415,000.00 | 1,471,865,000.00 | 1,486,432,000.00 | 1,472,594,000.00 | 1,470,945,000.00 | 1,448,517,000.00 |
| Total equity | 1.43B | 1.42B | 1.39B | 1.39B | 1.34B | 1.31B |
| Retained earnings | -16.32B | -16.36B | -16.41B | -16.43B | -16.49B | -16.53B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -4.86M | 29.87M | -53.51M | 193.99M | 189.29M | 350.02M | 293.68M | 294.36M |
| Depreciation & amortization | 35.60M | 44.95M | 78.09M | 219.62M | 267.78M | 348.72M | 382.84M | 376.43M |
| Free cash flow | -13.27M | 18.97M | -79.55M | 130.06M | 16.53M | 193.67M | 169.63M | 137.33M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 330.84M | -- | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 423.99M | 514.35M | 733.32M | 893.48M | 918.18M | 1.12B | 1.30B | 781.08M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 15.92M | 91.43M | 99.26M | 87.74M | 9.52M | 64.66M |
| Depreciation & amortization | 90.17M | 94.89M | 92.15M | 99.22M | 94.19M | 92.41M |
| Free cash flow | -15.67M | 31.63M | 67.95M | 53.42M | -26.31M | 23.07M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 1.19B | 679.62M | 726.25M | 781.08M | 750.74M | 774.35M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -12.35 | -9.75 | -5.74 | -2.69 | -148.85 | -9.51 | -52.46 | -13.93 |
| ROA %i | -8.25 | -6.31 | -5.01 | -2.42 | -123.73 | -5.04 | -25.32 | -6.28 |
| ROIC %i | -7.11 | -4.98 | -4.61 | -2.13 | -128.65 | -6.14 | -29.38 | -7.81 |
| 5-year avg ROE %i | -- | -37.46 | -18.23 | -11.51 | -35.88 | -35.31 | -43.85 | -45.49 |
| EBIT margin %i | -16.95 | -14.54 | -47.12 | -14.97 | -567.30 | -7.58 | -37.74 | -8.53 |
| FCF / sales %i | -- | 3.43 | -- | 6.40 | 0.69 | 7.44 | 6.60 | 5.43 |
| Current ratioi | 8.53 | 6.52 | 3.19 | 3.70 | 3.29 | 3.54 | 1.77 | 2.77 |
| Quick ratioi | 8.36 | 6.37 | 2.87 | 3.28 | 2.89 | 3.22 | 1.62 | 2.43 |
| Debt / assetsi | 27.12 | 29.35 | 8.32 | 7.22 | 36.52 | 36.25 | 45.06 | 36.39 |
| LT debt / equityi | 40.93 | 45.90 | 8.96 | 7.90 | 68.18 | 67.99 | 68.65 | 74.27 |
| Interest coveragei | -2.71 | -2.77 | -8.52 | -3.79 | -1,472.93 | -8.86 | -40.74 | -10.95 |
| Revenue CAGR (3Y) %i | 75.45 | 65.01 | 67.38 | 69.43 | 63.24 | 33.49 | 8.13 | 1.68 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -4.49 | -- | 9.26 | 102.54 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -54.49 | -14.18 | -15.42 | -13.93 | -12.39 | -12.99 |
| ROA %i | -26.07 | -6.46 | -6.98 | -6.28 | -5.48 | -6.28 |
| ROIC %i | -30.29 | -8.43 | -8.81 | -7.81 | -6.74 | -7.67 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -39.24 | -8.25 | -9.04 | -8.53 | -6.59 | -6.53 |
| FCF / sales %i | 7.07 | 5.95 | 5.54 | 5.43 | 5.04 | 4.75 |
| Current ratioi | 1.68 | 2.67 | 2.70 | 2.77 | 2.80 | 0.83 |
| Quick ratioi | 1.51 | 2.27 | 2.33 | 2.43 | 2.40 | 0.73 |
| Debt / assetsi | 46.07 | 35.77 | 36.20 | 36.39 | 36.98 | 37.56 |
| LT debt / equityi | 71.90 | 72.09 | 74.12 | 74.27 | 76.89 | 2.25 |
| Interest coveragei | -41.88 | -9.22 | -10.57 | -10.95 | -8.58 | -8.15 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Integrated Care is the largest reported line at 64.97% of revenue, across 2 reported segments.
- BetterHelp follows at 35.03%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Integrated Care64.97%
BetterHelp35.03%
Quote time 2026-10-08 09:19:52 · For reference only, not investment advice and not tailored to your situation.